Definium Therapeutics Beheer
Beheer criteriumcontroles 1/4
De CEO Definium Therapeutics is Rob Barrow, benoemd in Jun2021, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.77M, bestaande uit 5.1% salaris en 94.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.39% van de aandelen van het bedrijf, ter waarde $ 9.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 4.6 jaar.
Belangrijke informatie
Rob Barrow
Algemeen directeur
US$12.8m
Totale compensatie
| Percentage CEO-salaris | 5.13% |
| Dienstverband CEO | 4.9yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 1.5yrs |
| Gemiddelde ambtstermijn bestuur | 4.6yrs |
Recente managementupdates
Recent updates
Seeking Alpha • Apr 17
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones
Summary Definium Therapeutics, Inc. is maintained at a Strong Buy due to imminent 2026 catalysts and robust late-stage pipeline progress. DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD. DT402 targets a large unmet need in adult ASD, leveraging a differentiated R(-)-MDMA profile with prior phase 1 safety validation. With $411.6M cash and no near-term funding needs, DFTX is well-positioned to execute through multiple clinical milestones into 2028. Read the full article on Seeking Alpha
Nieuw narratief • Apr 02
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Mar 19
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Mar 04
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 21
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Summary Initiating coverage on Mind Medicine with a Hold rating due to regulatory uncertainties around rescheduling Schedule I compounds for medical use. Despite strong cash resources and promising Phase 3 trials, regulatory delays could hinder MNMD's patient access and market entry. The global GAD, MDD, and ASD markets present significant growth opportunities, but MM120 faces competition and unique safety and scheduling issues. Positive Phase 3 outcomes could drive regulatory progress, but until FDA and DEA clear rescheduling, broad patient access and reimbursement remain uncertain. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Summary Mind Medicine (MindMed) Inc.'s stock has surged over 160% since my October 2022 “Hold” call, driven by positive Phase 2b data for MM120 in treating GAD. Despite financial stability and promising Phase 3 trials, significant hurdles remain, including DEA rescheduling of LSD and FDA approval challenges. The company faces issues with patenting naturally occurring substances and potential reluctance from insurers and physicians to adopt psychedelic therapies. While MindMed shows progress, I remain cautious due to regulatory and commercial obstacles, maintaining my “Hold” rating on MNMD amidst ongoing uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Summary Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. Investors should watch for key milestones in 2026 and consider risks related to trial outcomes and regulatory approval for MM-120 and MM-402. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Psychedelic Stocks: Focus On Their Cash
Summary Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. Major players in the psychedelic medicine space are well-funded, moving into Phase 3 trials, with potential for significant milestones in the near future. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033. MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA. Read the full article on Seeking AlphaSeeking Alpha • Apr 04
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Summary Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Read the full article on Seeking AlphaSeeking Alpha • Feb 02
Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Summary Primary endpoint met of HAM-A scores at week 4 met in phase 2b MMED008 study, when Generalized Anxiety Disorder patients were given MM-120. 12-week HAM-A results from phase 2b MMED008 study in GAD to be released end of Q1 of 2024 with full data set at upcoming medical meeting in 2024. End of phase 2 meeting with FDA to discuss advancement of MM-120 for GAD expected in the 1st half of 2024; Phase 3 trial initiation expected 2nd half of 2024. The generalized anxiety disorder market size is estimated to reach $8.1 billion by 2027. Read the full article on Seeking AlphaAnalyseartikel • May 23
Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Feb 07
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Oct 19
MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Summary MindMed is one of a handful of listed companies developing psychedelic drugs to treat depressive conditions. The company has two Phase 2 trials ongoing of the lead candidate - a formulation of LSD in GAD and ADHD. Results are expected in late 2023. A Phase 1 trial initiation for an MDMA based therapy in Autism Spectrum Disorder has also been promised. Some shareholders have turned on management, accusing it of lacking a coherent strategy. The company recently completed a reverse stock split to avoid delisting. Psychedelic drug developers face significant issues trying to get their drugs approved as they are controlled substances. Progress is being made, but it looks as though the market is passing on MindMed. Investment Overview I last covered MindMed (MNMD), a company developing "pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes", for Seeking Alpha back in July. In my last note, I discussed some of the difficulties facing drug developers working with psychedelic drugs - which include, besides MindMed, listed companies such as Compass Pathways (CMPS), Bright Minds Biosciences (DRUG), Atai Life Sciences (ATAI), Cybin Inc. (CYBN), and GH Research (GHRS). The biggest stumbling block is the fact that psychedelic substances such as LSD and MDMA - the substances behind MindMed's two lead products, MM-120, and MM-402 - are listed by the US' Drug Enforcement Agency ("DEA") as "controlled substances", and fall into the "Schedule 1" category. Schedule 1 drugs are defined as follows: Schedule I substances by definition have a high potential for abuse, have no currently "accepted medical use" in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States. That means that additional permissions to work with the drugs must be sought and obtained, and also that before LSD or MDMA could be marketed for commercial medical use they would have to be rescheduled, which requires the approval of both the DEA and FDA. Another major issue is that it is hard to obtain patents for drugs like LSD, MDMA, or Psilocybin. According to an article from Harvard Law Review, there are several reasons for this. Psychedelics, for example, are "products of nature that should remain affordable and widely available". These drugs have also been used by indigenous communities for generations. Another objection is that awarding patents to a handful of companies may restrict or stifle innovation, and restrict access to therapies. Further adding to the difficulties is the fact that, although scientists worked with psychedelics in the '50s and '60s, they became banned substances in the '70s as a result of President Nixon's War on Drugs. In short, psychedelics is a tricky landscape to navigate, but it hasn't stopped the above companies from attempting to prove their usefulness and trying to secure patents for their use (under certain prescribed conditions such as at a designated clinic under the supervision of a trained psychotherapist), and secure approval for commercial medical use. Share price performance of selected companies developing psychedelic drugs. (TradingView) As we can see above, however, over the past year the falling share prices of these companies illustrates the difficulty of the mountainous task faced and the market's fading belief that it can be scaled successfully. MindMed's share price has been the hardest hit. As I predicted they might be in my previous note, MindMed was forced to complete a 1-15 reverse stock split at the end of August in order to regain compliance with Nasdaq listing laws (which require share prices to trade >$1) although the share price has sunk from a price of $15 post split, to just $3 at the time of writing. With the stock price currently so cheap, despite the headwinds listed above, is there still a case for investing in the company? In this post, I'll examine recent progress in some more detail and speculate about whether there may be a case for an upside. Market Overview The use of psychedelics to treat depressive diseases certainly has its advocates and has always done so historically - in 21 studies prior to 1974, LSD use led to a 95% reduction in symptoms in a patient population of 512 patients with anxiety, depression, and neurotic illnesses, according to data shared in a recent MindMed investor presentation. The hard part has been winning mainstream approval for the use of psychedelics to treat mainstream conditions, although there are signs that may be changing. The FDA has designated MDMA and Psilocybin as "Breakthrough Therapies - in 2017 and 2018 respectively - there are several non-profit organisations promoting their medical use and some representation within government. Sports personalities - such as ice-hockey player Daniel Carcillo, who has founded a psilocybin startup, and NFL star Aaron Rodgers, who has spoken about using Ayahuasca to improve his performances -have helped to spread the message. Psilocybin and Ayahuasca are also seen as a potential solution to the mental health crisis amongst veterans, illustrated by the emergence of the Heroic Hearts Project, which runs Ayahuasca retreats and is working with Imperial College London to study Psilocybin as a means of treating head trauma and post traumatic stress disorder ("PTSD"). The market for psychedelic drugs has been estimated to be ~$3.2bn, rising to $6.3bn by 2026 as their value becomes increasingly recognised for treatment of different types of depressive treatments, such as bi-polar, suicidal ideation, drug and alcohol dependence, and anxiety. Johnson & Johnson's (JNJ) nasal spray Spravato - chemically similar to the party drug ketamine - was approved for commercialisation in 2019, although JNJ has not been sharing sales figures and the market has apparently been sceptical. Relmada's depression candidate REL-1017 - which has a similar mechanism of action to Spravato - failed to meet endpoints in a pivotal study last week. To summarise, treating depressive disorders is big business for Big Pharmas - Eli Lilly's (LLY) Zyprexa, indicated for schizophrenia is a >$400m per annum seller, and AbbVie's (ABBV) Vraylar earned revenues of >$1.7bn in 2021 for example - and for smaller commercial-stage biotechs - Vanda Pharmaceuticals (VNDA) Fanapt, and Intra-Cellular's (ITCI) Caplyta, both generate >$100m revenues per annum. If psychedelic drug developers could find a way to prove its drugs work, win an FDA approval, and have the drug reclassified from Schedule 1 to Schedule 2 (or 3, 4, or 5) there is a market ready to exploit, given that, despite their ability to drive sales, most approved depressive condition drugs have a very limited clinical benefit - the bar for approval is therefore set low. Pharmas have generally been uninterested in developing psychedelic drugs since they are difficult to obtain patents for, meaning the return on investment is much lower, but companies such as MindMed and Compass Pathways are finding creative ways to patent the overall treatment experience, rather than the drug itself, although many of MindMed's 26 pending US applications are in traditional areas such as compositions of matter, methods of treatment, as well as diagnostic devices and analytics related to psychedelics. MindMed's Potential Path To Approval On its Q222 earnings call, MindMed advised analysts that after a review of its pipeline assets it had decided to focus resources specifically on just two assets - MM120 - LSD D-tartrate - and MM402 - MDMA. That means that development of MM-110 - Zolunicant hydrochloride, a derivative of ibogaine - indicated for opioid withdrawal - has been halted for the time being. MM-110 had returned positive data from a Phase 1 placebo controlled study of 108 healthy volunteers, but the FDA subsequently requested additional preclinical characterisation of the drug, which must be completed before a Phase 2a study can begin. MM120 - a proprietary pharmaceutically optimized form of lysergic acid diethylamide ("LSD") - is being developed for both Generalized Anxiety Disorder ("GAD") and Attention Deficit Hyperactivity Disorder ("ADHD"). In GAD, a Phase 2b study has been initiated which uses doses of 25mg, 50mg, 100mg, and 200mg over a 4-week period, with follow-ups at 8 and 12 weeks. Enrollment target is 200 patients, and primary endpoint is the Hamilton Anxiety Rating Scale (HAM-A), with secondary endpoints being other depression rating scales such as the Montgomery-Åsberg Depression Rating Scale ("MADRS"). In ADHD the dose level will be 20mg q3d over a 6-week period, with a follow up at 10 weeks. The Primary Endpoint will be Adult ADHD Investigator Symptom Rating Scale ("AISRS"). Results from each trial are not expected until late 2023, however, presumably due to the difficulty of enrolling patients. The conditions of administration are almost as important as the drug itself, with continual monitoring of the patients through pre-treatment, treatment, and post-treatment, plus professional psychological support if necessary, remote monitoring, and monitored sessions. In collaboration with the University Hospital Basel, MindMed has been carrying out a Phase 2, placebo controlled, investigator initiated clinical trial of LSD and the treatment of anxiety disorders at London's PSYCH Symposium. On the Q222 earnings call, MindMed management reported that: The study drug was well tolerated and then a dose of 200 micrograms resulted in significant and strong reductions of Global State-Trait Anxiety Inventory, or STAI-G 16-weeks after treatment in the between subjects analysis, with a statistically significant improvement from baseline compared to placebo. This is important because it shows that LSD can have a positive effect and suggests that the two ongoing clinical trials can deliver the required results to make a push for FDA authorisation a genuine possibility. Compass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a psychologist on hand at all times. In summary, MindMed ought to have a good chance of success in these trials, but in the meantime, the company must deal with more severe headwinds that threaten to overwhelm the company. On the MM-402 front, management discusses some positive preclinical data on its last earnings call, and adds that: In addition to our collaboration with University Hospital Basel, we expect to initiate a comparative Phase 1 pharmacokinetics and pharmacodynamics trial of RS and recite MDMA and healthy volunteers in the third quarter of 2022. Objections to MindMed's Approach From Former CMO So far in this post, we have dealt mainly with the positive aspects of MindMed's business - and actually, there is a further positive in the fact that management says it has a cash runway that ought to last until 2025, taking in the clinical readouts in the GAD and ADHD studies with MM-120. What, then is the reason for the rapidly declining share price? Most of all, in my view, it relates to two things - the market's lack of belief that the FDA - or overseas governments - will permit psychedelic drugs to be approved and rescheduled, and the market's lack of faith in MindMed's management.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$238m |
| Dec 31 2025 | US$13m | US$655k | -US$184m |
| Sep 30 2025 | n/a | n/a | -US$168m |
| Jun 30 2025 | n/a | n/a | -US$115m |
| Mar 31 2025 | n/a | n/a | -US$78m |
| Dec 31 2024 | US$3m | US$624k | -US$109m |
| Sep 30 2024 | n/a | n/a | -US$98m |
| Jun 30 2024 | n/a | n/a | -US$102m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$599k | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$75m |
| Mar 31 2023 | n/a | n/a | -US$63m |
| Dec 31 2022 | US$5m | US$672k | -US$57m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$98m |
| Dec 31 2021 | US$12m | US$350k | -US$93m |
Compensatie versus markt: De totale vergoeding ($USD 12.77M ) Rob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.02M ).
Compensatie versus inkomsten: De vergoeding van Rob is gestegen terwijl het bedrijf verliesgevend is.
CEO
Rob Barrow (36 yo)
4.9yrs
Tenure
US$12,767,442
Compensatie
Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$12.77m | 0.39% $ 10.0m | |
| Chief Financial Officer | less than a year | US$5.33m | geen gegevens | |
| Chief Medical Officer | 5.3yrs | US$4.00m | 0.26% $ 6.6m | |
| Co-Founder & Clinical Advisor | no data | US$501.19k | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Pharmaceutical Development & Operations | 1.3yrs | geen gegevens | geen gegevens | |
| VP & Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 3.1yrs | US$1.16m | 0.089% $ 2.3m | |
| Vice President of Corporate Communications | 1yr | geen gegevens | geen gegevens | |
| Chief Corporate Affairs Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Regulatory & Quality Assurance Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 1.2yrs | geen gegevens | geen gegevens |
1.5yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DFTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$12.77m | 0.39% $ 10.0m | |
| Independent Chairperson | 4.7yrs | US$496.83k | 0.015% $ 388.5k | |
| Independent Director | 2.9yrs | US$458.83k | 0.0097% $ 249.2k | |
| Independent Director | 3.8yrs | US$457.83k | 0.016% $ 414.1k | |
| Chair of Scientific Advisory Board | 5.2yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Independent Vice Chairman | 4.7yrs | US$484.83k | 0.0036% $ 91.2k | |
| Independent Director | 3.8yrs | US$456.83k | 0.016% $ 414.1k | |
| Member of Scientific Advisory Board | 1.6yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.5yrs | geen gegevens | geen gegevens |
4.6yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DFTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/29 23:36 |
| Aandelenkoers aan het einde van de dag | 2026/05/29 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Definium Therapeutics, Inc. wordt gevolgd door 22 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Joel Beatty | Baird |
| null null | Baird |
| Christopher Chen | Baird |